ask our doctors

Hypophosphatemia

Get the facts on Hypophosphatemia treatment, diagnosis, staging, causes, types, symptoms. Information and current news about clinical trials and trial-related data, Hypophosphatemia prevention, screening, research, statistics and other Hypophosphatemia related topics. We answer all your qestions about Hypophosphatemia.

Question: Hypophosphatemia is an x-linked dominant disorder that causes a type of rickets. Which statement about....? Hypophosphatemia is an x-linked dominant disorder that causes a type of rickets. Which statement about people with this disorder is likely true a) Affected heterozygous females would transmit the trait to all their sons b) Affected males would produce all affected sons and no affected daughters c) Affected male would produce all affected daughters and no affected sons d) Affected heterozygous females would transmit the trait to all their daughters

Answer: I think option d is the right one- affected heterozygous females would transmit the trait to all their daughters. Since its an X- Llinked disorder i guess it might be the answer.


Hypophosphatemia News

Cabozantinib Shows Encouraging Activity in Advanced Renal Cell Carcinoma

Drug Discovery & Development
The most frequently reported grade ? 3 adverse events (AEs), regardless of causality were: hypophosphatemia (36%), hyponatremia (20%), both manageable with substitution with or without cabozantinib dose reduction or interruption, fatigue (16%), ...
 

Cabozantinib Shows Encouraging Activity in Heavily Pretreated Patients With ...

EON: Enhanced Online News (press release)
The most frequently reported grade ? 3 adverse events (AEs), regardless of causality were: hypophosphatemia (36%), hyponatremia (20%), both manageable with substitution with or without cabozantinib dose reduction or interruption, fatigue (16%), ...
 

Quebec is first in Canada to provide access to innovative treatment, XGEVA

Canada NewsWire (press release)
9 The most common adverse events observed in clinical trials of patients receiving XGEVA versus zoledronic acid were fatigue (27.1 per cent vs 27.0 per cent respectively) and asthenia (21.4 per cent vs 21.9 per cent respectively); hypophosphatemia ...
 

U.S. Food And Drug Administration Approves Pfizer's INLYTA(R) (axitinib) For ...

MarketWatch (press release)
... hyperglycemia (89%), hyperlipemia (87%), hypertriglyceridemia (83%), elevated alkaline phosphatase (68%), elevated serum creatinine (57%), lymphopenia (53%), hypophosphatemia (49%), thrombocytopenia (40%), elevated AST (38%), and leukopenia (32%).
 

U.S. Food and Drug Administration Approves New Formulations of Viread(R) for ...

MarketWatch (press release)
New onset or worsening renal impairment: New onset or worsening renal impairment, including cases of acute renal failure and Fanconi syndrome (renal tubular injury with severe hypophosphatemia), have been reported with the use of Viread.
 

Cabozantinib Shows Encouraging Activity in Heavily Pretreated Patients With ...

PharmaLive.com (press release)
The most frequently reported grade ? 3 adverse events (AEs), regardless of causality were: hypophosphatemia (36%), hyponatremia (20%), both manageable with substitution with or without cabozantinib dose reduction or interruption, fatigue (16%), ...